^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PD-L1 inhibitor

    Related drugs:
    1d
    DETERRED: MPDL3280A With Chemoradiation for Lung Cancer (clinicaltrials.gov)
    P2, N=52, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    Tecentriq (atezolizumab) • carboplatin • paclitaxel
    1d
    ROSETTA GI 204: A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) (clinicaltrials.gov)
    P2/3, N=690, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    Opdivo (nivolumab) • 5-fluorouracil • pumitamig (BNT327)
    1d
    Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery (clinicaltrials.gov)
    P2, N=27, Recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine
    1d
    Potent antitumor activity through dual targeting of PD-L1 and TGF-β pathways in the glioma tumor microenvironment. (PubMed, J Immunother Cancer)
    Our findings provide strong support for the combined targeting of TGF-β and PD-L1 as a promising immunotherapeutic strategy to overcome immunosuppressive barriers in glioblastoma and induce potent antitumor responses.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    PD-L1 expression
    |
    bintrafusp alfa (M7824)
    1d
    Adebrelimab Neoadjuvant Treatment for Resectable ESCC (clinicaltrials.gov)
    P=N/A, N=22, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New trial
    |
    cisplatin • albumin-bound paclitaxel • TheraCIM (nimotuzumab) • AiRuiLi (adebrelimab)
    2d
    Early mortality in atezolizumab/bevacizumab for HCC is associated with impaired liver function and alterations of systemic immunity. (PubMed, JHEP Rep)
    We identified EM to represent a common event in patients with HCC after treatment initiation and demonstrated impaired liver function, elevated biomarkers of inflammation, and reduced lymphocyte frequencies and increased regulatory T cell activity to be associated with increased EM risk. These findings can help clinicians identify patients with HCC at high risk of EM, enabling adequate and informed decision-making regarding end-of-life care and palliative treatment.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD44 (CD44 Molecule) • CRP (C-reactive protein)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    2d
    ALICE: Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma (clinicaltrials.gov)
    P2/3, N=196, Recruiting, UNICANCER | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • oxaliplatin
    2d
    Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=500, Not yet recruiting, Shanghai Huaota Biopharmaceutical Co., Ltd.
    New P3 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • pemetrexed
    3d
    SKYSCRAPER-15: A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (clinicaltrials.gov)
    P3, N=56, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    3d
    Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours (clinicaltrials.gov)
    P2, N=126, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2025 --> Jun 2026
    Trial completion date
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • falbikitug (AZD0171)
    3d
    SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    paclitaxel • capecitabine • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • retlirafusp alfa (SHR-1701)
    3d
    Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy (clinicaltrials.gov)
    P2, N=69, Active, not recruiting, Centre Leon Berard | Recruiting --> Active, not recruiting | Trial completion date: Aug 2024 --> Dec 2026 | Trial primary completion date: Aug 2023 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Tecentriq (atezolizumab)